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INTRODUCTION
Lung cancer is the most common fatal cancer worldwide
and has become the leading cause of cancer deaths in Korea.
The number of new cases will continue to rise (1). The risk
of human cancer can be associated with environmental, occu-
pational, and recreational exposures to carcinogens (2). Onco-
genesis is related with epigenetic changes, oncogenes, tumor
suppressor genes, apoptosis, and genetic changes associated
with DNA repair. There have been many investigations on
the prognostic role of p53, bcl-2, and Ki-67 expression in
non-small cell lung cancer (NSCLC). Early reports of p53
mutation suggested a variable relationship to survival (3, 4).
Another study showed that p53 mutations detectable in tumor
tissues had been shown to be an independent marker for the
poor prognosis in resectable stage I NSCLC (5). Data on bcl-
2 expression from a study on NSCLC patients showed posi-
tive correlations with longer survival (6). There were reports
on an inverse relationship between bcl-2 and p53 in NSCLC
(7, 8). However, another studies did not support a relevant
prognositic role for p53, bcl-2, or Ki-67 immunohistochem-
ical markers in NSCLC regardless of stage (9, 10). No rela-
tionship was observed between the expression of Ki-67 and
that of bcl-2. The relationship between a positive rate for
Ki-67 and prognosis remains unclear (11). Small cell lung
cancer (SCLC) has a poor prognosis. Most of the patients carry
a large burden at the time of diagnosis. SCLC has been stud-
ied less than NSCLC. There was a report that bcl-2 expres-
sion did not influence survival in SCLC (12). We conducted
a retrospective study on the value of mutant p53, bcl-2, and
Ki-67 expressions in SCLC patients from Korea Cancer Cen-
ter Hospital. 
MATERIALS AND METHODS
All of the patients were primarily diagnosed as SCLC at
the Department of Internal Medicine of Korean Cancer Cen-
ter Hospital between February 1997 and December 2002.
Seventy-five of 107 SCLC patients were treated. Immuno-
histochemical (IHC) stainings for mutant p53, bcl-2 and Ki-
67 expressions were performed in the 66 paraffin-embedded
biopsy samples among the 75 member treatment group. The
study group included patients (57 males and 9 females, 61 yr
mean age) with cytologically or histopathologically diagnosed
SCLC. Histopathological diagnoses were done by broncho-
scopic biopsy, lymph node biopsy, and percutaneous lung gun
biopsy. Staging procedures included physical examination, chest
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Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and
Ki-67 in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is one of the most fatal cancers in humans and many
factors are known to be related to its poor prognosis. Immunohistochemical (IHC)
stainings were done on SCLC specimens in order to investigate the prognostic
value of the apoptosis-related gene expression and the tumor proliferative maker,
and the relationships among these IHC results and patients clinical characteristics,
chemoresponsiveness, and survival were analyzed. The medical records of 107
patients were reviewed retrospectively. IHC stainings for p53, bcl-2 and Ki-67 expres-
sions were performed in the 66 paraffin-embedded biopsy samples. Sixty-six out
of the 107 patients were evaluable for response rate and survival. The overall response
rate was 75% (95% Confidence Interval=74-76%) and the median survival time was
14 months. The median survival time of limited stage was 16 months and that of
extensive stage was 10 months. The prevalence of p53, bcl-2 and Ki-67 expression
was 62%, 70%, and 49%, respectively. There were no correlations among the im-
munoreactivities of p53, bcl-2 and Ki-67 with clinical stage, chemoresponsiveness
or overall survival. The clinical stage was the only prognostic factor influencing sur-
vival. The expression rates of p53, bcl-2, and Ki-67 were relatively high in SCLC
without any prognostic significance. The exact clinical role of these markers should
be defined through further investigations.
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radiography, chest computed tomography (CT) scan, and bone
scintigraphy. Brain CT/magnetic resonance image (MRI),
bone marrow biopsy and other studies were optional in asymp-
tomatic patients but mandatory in those with symptoms
suggesting disseminations. Patients were staged as either
limited, with disease confined to one hemithorax, or exten-
sive, with disease beyond one hemithorax. All patients were
administered one of the three chemotherapy regimens: cis-
platin and etoposide (EP); cyclophosphamide, adriamycin,
and vincristine (CAV); etoposide and carboplatin (EC). We
established the principle that all limited disease patients would
be treated by radiotherapy if the chemotherapy were effec-
tive. And then 40 patients out of all limited disease patient
were treated by radiotherapy. Response categories i.e. com-
plete response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD) were evaluated according to
new response evaluation criteria in solid tumor (RECIST)
guidelines (13). The CR and PR patients were considered
responsive. Survival was defined as time lapse from the day
of first chemotherapy course until the day of death.
Five-micrometer thickness, paraffin-embedded, tissue sec-
tions were deparaffinized in xylene and hydrated in a graded
ethanol series. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide in methanol. Tissue sections
were heated in 10 mM sodium citrate, pH 6.0, in a microwave
oven for 10 min to expose the antigens. Sections were then
washed with Tris-buffered saline (TBS). The streptavidin-
biotin-peroxidase complex technique (universal LSAB kit,
DAKO, Glostrup, Denmark) was used for immunohisto-
chemical stain. The sections were incubated overnight at 4℃
with the three monoclonal antibodies: p53 (1:50, DAKO,
Glostrup, Denmark), bcl-2 (1:40, DAKO) and Ki-67 (1:50,
Zymed, San Francisco, CA, U.S.A.). Sections were then washed
with TBS and incubated with biotinylated secondary anti-
body for 30 min at room temperature. After washing, the
sections were incubated with peroxidase-labelled streptavidin
at room temperature for 30 min. Diaminobenzidine/hydro-
gen peroxidase was used as a chromogen and sections were
counterstained with hematoxylin. When the cell nuclei were
stained strongly with dark brown color, the cells were con-
sidered to be positive for p53 and Ki-67. Bcl-2 expression
was noted in the cytoplasm. If more than 10% of the tumor
cells were positively stained, it was considered as positive for
p53 and bcl-2. In the case of Ki-67, the labeling index was
determined by scanning areas with uniformly stained cells
at a low magnification, followed by counting of the cells at
high power field (×400). Appropriate positive and negative
controls were used for all the procedures.
Median values and ranges were used to calculate patient
characteristics and to compare the factors. To examine factors
affecting survival, the following variables were analyzed: age,
sex, disease extent, performance status, and Ki-67, p53, and
bcl-2 expression. Each of these variables was divided into two
categories as follows: age was divided by mean age, i.e., less
than 60 yr vs. more than or equal to 60 yr; sex, male vs. female;
disease extent, limited disease (LD) vs. extended disease (ED);
performance status (PS), good (PS 0-1) vs. poor (PS 2-4); Ki-
67, equal to or greater than 50% vs. less than 50%; p53 and
bcl-2, positive vs. negative. To compare the response rate, chi-
square test was used. Survival was assessed by the Kaplan-
Meier method and compared with log-rank test. Hazard ratio
and its 95% confidence interval for each variable were esti-
mated by Cox proportional hazard model. A p-value lower
than 0.05 was considered statistically significant. Chi-square
test with Fisher exact test were used as appropriate. SPSS for
Windows, 11.0 standard version, was used for all analysis.
RESULTS
Patient characteristics are shown in Table 1. Overall response
rate for evaluable 66 patients were 72%. There was no dif-
ference of the response rate among three regimens (EP, 69%;
CAV, 65%; EC, 75%; p=0.83). Forty-one (62%) out of the
66 patients were positive for p53 antibodies; 25 (40%) with
limited disease (LD) and 16 (24%) with extensive disease
(ED) (p=0.36). The response rate for the positive p53 group
was 68%, that for the negative group was 84% (p=0.15). Sur-
vival data were available for 66 patients. Median survival
was 13 months for the positive p53 group, and 16 months
for the negative group (p=0.50). There were no significant
differences in sex, age, disease extent, performance status,
and survival between patients with and without mutant p53
antibodies (Table 2). According to the analysis of prognostic
factors which influenced chemotherapeutic response rate and
survival, only the extent of the disease was significant for
patient survival by univariate and multivariate analysis (Table
3) (Fig. 1). Median survival for the entire group was 15 mon-
Variable No. of cases
Sex Male 57
Female 9
Age (yr) Median 59
Range 40-74
Mean 61.03±6.40
Performance status 0 30
12 3
21 2
31
40
Chemotherapy Cisplatin+Etoposide 25
regimen Cyclophosphamide+adriamycin+ 17
vincristine
Carboplatin+Etoposide 24
Stage LD 43
ED 23
Total 66
Table 1. Patient characteristics
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ths; 16 months for LD patients, and 10 months for ED pati-
ents (p=0.04). We also analyzed the survival between posi-
tive and negative p53 groups in LD patients or ED patients.
In LD patients, median survival was 15 months for the pos-
itive p53 group, and 18 months for the negative group (p=
0.37). In ED patients, median survival was 10 months for
positive p53 and 12 months for negative (p=0.87). No cor-
relation was found between survival and p53 expression in
either LD or ED patients. Therefore p53 was not a useful
prognostic indicator of SCLC. 
For bcl-2, 45 (70%) out of 64 patients were positive; 26
(40%) with LD and 19 (30%) with ED (p=0.15) (Table 2).
The response rate was 75% for the positive bcl-2 group, and
73% for the negative group (p=0.72). Median survival was
16 months for positive bcl-2, and 15 months for the nega-
tive group (p=0.46). In LD patients, median survival was 15
months for the positive bcl-2 group and 19 months for the
negative group 19 months (p=0.37). In ED patients, median
survival was 9 months for positive bcl-2, and 12 months for
negative (p=0.16). No correlation was found between sur-
vival and bcl-2 expression in either LD or ED patients. Like
mutant p53, there were no significant differences in sex, gen-
der, disease extent, performance status, and survival between
patients with and without bcl-2 expression.
We separately analyzed Ki-67 antigen expression both
above and below 50%. Thirty-two (49%) out of 65 were in
the above 50% group, 22 (34%) with LD and 10 (15%) with
ED (p=0.60) (Table 2). The response rate was 69% for the
above 50% group, and 79% for the below group (p=0.55).
Median survival was 16 months for the above 50% group,
and 15 months for the below group (p=0.21). In LD patients,
median survival was 16 months for the above 50% group,
and 16 months for the below group (p=0.37). In ED patients,
median survival was 12 months for the above 50% group and
10 months for the below group (p=0.65). No correlation was
found between survival and Ki-67 expression in either LD
or ED patients. There were no significant differences in sex,
gender, disease extent, performance status, and survival accord-
ing to Ki-67 expression.
Univariate
analysis
p-value
Multivariate
analysis
p-value
Performance status 0-1 0.049 0.058
2-4
Sex M 0.732 0.853
F
Age (yr) ≥60 0.094 0.234
<60
Stage LD 0.032 0.047
ED
Radiation therapy Done 0.252 0.153
Not done
Table 3. Prognostic factor analysis
LD, limited disease; ED, extensive disease.
p53 (%)
+ - p value
Bcl-2 (%)
+ - p value
Ki-67 (%)
≥50% <50% p value
Sex (M) 53.0 33.3 0.762 59.4 26.6 0.736 42.0 44.6 0.848
Sex (F) 9.0 4.5 10.9 3.1 7.7 6.2
Age ≥60 yr 21.2 15.1 0.632 21.2 14.1 0.492 12.3 24.6 0.108
Age <60 yr 40.9 21.7 48.4 15.6 36.9 26.2
Limited disease 37.9 27.3 0.362 40.6 23.4 0.154 33.8 32.3 0.601
Extensive disease 24.2 10.6 29.7 6.3 15.4 18.5
Performance status
0-1 45.5 34.8 0.062 54.7 25.0 0.652 38.5 41.5 0.832
2-4 16.7 3.0 15.6 4.7 10.8 9.2
Response rate 68 84 0.157 7.6 73.7 0.720 36.8 78.8 0.574
Median survival 13 16 0.507 16 15 0.463 16 15 0.210
(month)
Table 2. Response rate and median survival according to p53, bcl-2 and Ki-67
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Fig. 1. Survival according to stage.
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DISCUSSION
The p53 protein is recognized as an important cell regu-
latory factor that arrests the growth of cells containing dam-
aged DNA. A reversible arrest in the G1 phase of the cell
cycle enables DNA repair before DNA synthesis. When
appropriate repair is not possible, p53 expression may trig-
ger apoptosis, a reversible process culminating in cell death.
If normal, wild type p53 function is lost, the treatment is
relatively resistant, as a result of deficiency of p53-dependent
apoptosis (14, 15). The p53 mutation is the most common
genetic mutation in cancer. Thus, the mutated gene loses its
natural tumor suppressor function allowing damaged cells
to divide unchecked and finally to become malignant cells.
There are still controversies concerning the prognosis and
survival in lung cancer patients. Some studies reported that
p53 mutation had been associated with poor prognosis and
shorter survival in NSCLC (5, 8, 16, 17). However, some
others reported no such correlation in NSCLC (3, 9, 10, 18).
Others reported a favorable prognosis in NSCLC (4, 19). There
have been fewer studies in SCLC than in NSCLC. Some studies
showed that bcl-2 expression and p53 mutation had no rela-
tion to survival in SCLC (9, 10, 12, 20). Another study divid-
ed their SCLC patients into limited and extensive-stage dis-
ease, after which p53-antibody positivity emerged as an inde-
pendent marker of poor prognosis in LD but had no rela-
tion to survival (21). One study indicated that p53 played
an important role as a determinant of chemosensitivity in
SCLC and that p53 immunostaining could be used in clini-
cal practice to determine the presence of tumor-chemoresis-
tance (22). Kenichi et al. reported that patients with expres-
sion of mutant p53 protein showed lower response rate than
those having p53-negative tumors and were less sensitive to
anticancer drugs (23). Our study, however, indicated that
p53 antibody had no relation to survival.
The bcl-2 proto-oncogene is encoded by a 230-kb gene
that gives rise to a 24- to 26-kDa protein that is localized in
the inner mitochondrial membrane, and, to a lesser extent,
in the cell membrane (24). The major function of bcl-2 appears
to be the inhibition of apoptosis or programmed cell death,
whereas bax, bad, bak, and others promote cell death (25). It
is well documented that bcl-2 becomes deregulated in tumor
cells as a result of translocation into the immunoglobulin
heavy-chain locus, and is therefore constitutively activated
in follicular lymphoma (26). In epithelial tumors, no genetic
change of bcl-2 has been demonstrated, in contrast to lym-
phocytic neoplasia. However, bcl-2 expression has been des-
cribed in a series of solid tumors, particularly in NSCLC and
in breast cancer (27). An in vitro study showed that bcl-2
expression may be related to chemoresistance due to inhibi-
tion of drug-induced apoptosis (28). Thus multidrug resis-
tance is probably linked, at least in part, to high levels of
bcl-2 expression. Bcl-2 blocks the cell death pathway (apop-
tosis) and is not directly associated with cell proliferation
(29). Studies examining the association of bcl-2 expression
with survival in NSCLC have been contradictory, with some
reporting bcl-2 as an indicator of better survival (6, 7), while
other showed no survival differences according to bcl-2 sta-
tus (30, 31). There have been few studies in SCLC. From our
results, bcl-2 expression was not an independent predictor
of survival in SCLC.
BrdU (bromodeoxyuridine), PCNA (proliferating cell nu-
clear antigen), Ki-67, and others have been used as cell pro-
liferation markers. PCNA, a 36-kilodalton, nuclear polypep-
tide that is related to cell proliferation, is identical to cyclin,
which is a protein that appears in the proliferative phase of
cells (32). Being synthesized during the late G1 to S phase,
PCNA is an auxillary protein for DNA polymerase  . Ki-
67, a more reliable proliferating marker, reacts with nuclear
antigen that is present only in proliferating cells (G1, S, G2,
and M phase), not in resting (G0) cells (33-35), and thereby
provides a reliable method for evaluating tumor growth frac-
tion in many malignant tumors, including lung cancer (36).
It appears to be a useful prognostic marker of NSCLC, espe-
cially in the early stage (37). Compared to p53 and bcl-2, the
relationship between Ki-67 and survival has been studied
less extensively in NSCLC, and especially so in SCLC. Our
results showed that Ki-67 expression had no relation to sur-
vival in SCLC.
From our results, the apoptosis-related genes, mutant p53
and bcl-2, and the proliferative marker, Ki-67, were found
to be useful in the diagnosis of SCLC patients because of their
relatively high prevalence (38, 39). However, as they did not
show clinical significance for prognosis or survival, further
investigation will be required to confirm the clinical role of
these markers.
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